Paris and Boston, May 31, 2023 – 6:30 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA), inventor of Cellvizio®, the multidisciplinary platform for confocal laser endomicroscopy by miniprobe and needle (p/nCLE), announces the implementation of an equity financing line with Vester Finance in the form of a PACEO limited to a maximum of 11.4% of the capital, as announced during the publication of the 2022 annual results.
Sacha Loiseau, President and CEO of Mauna Kea Technologies, said: “Our partnership with Tasly Pharmaceutical is proceeding according to plan, with an important milestone reached today with the receipt of an additional $2.5 million from the Joint Venture. Beyond this collaboration and the commercial momentum observed in the 1st quarter of 2023, it is important to maintain rigorous financial management and secure the Company’s financial visibility. This line of financing, voluntarily limited to a maximum of 11.4% of the capital, can be suspended at any time by the Company according to its real needs. We are reiterating here an operation already successfully carried out in the past alongside Vester Finance, which demonstrates our confidence in the quality and adaptability of its execution.”